Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

Dramatic Improvement in Dermatomyositis Skin Symptoms With First Approved Oral Agent

(MedPage Today) -- Patients with previously treated dermatomyositis had significant improvement in skin-related symptoms and quality of life when treated with the selective TYK2/JAK1 inhibitor brepocitinib (Lisraya), data from a randomized trial...

Dramatic Improvement in Dermatomyositis Skin Symptoms With First Approved Oral Agent

We haven't written up this one. MedPage Today has the full story — the link below goes straight to it.

Read the original at medpagetoday.com →

More in Health & Medicine

Psilocybin Prevents Chemotherapy-Related Peripheral Neuropathy in Mice

A study found that psilocybin given before chemotherapy prevented the onset of nerve injury in mouse models, even after repeated treatment cycles, and also protected tumor-bearing mice from…

  • Psilocybin prevents chemotherapy-related peripheral neuropathy in mice
  • Serotonin 2A receptors play neuroprotective role in mice model
  • Study suggests psilocybin as potential first-in-class CIPN prevention

More from Thursday 3 September →